Cargando…
The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions
AIM: We aimed to evaluate the 1-year efficacy and safety of low-frequency intravitreal bevacizumab in the treatment of macular edema due to retinal vein occlusions (RVOs). METHODS: The study comprised an interventional prospective study of patients with macular edema due to central retinal vein occl...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488787/ https://www.ncbi.nlm.nih.gov/pubmed/28790803 http://dx.doi.org/10.2147/OPTH.S137380 |
_version_ | 1783246717506813952 |
---|---|
author | Ivanovska Adjievska, Biljana Boskurt, Salih Orovcanec, Nikola Dimovska-Jordanova, Vesna |
author_facet | Ivanovska Adjievska, Biljana Boskurt, Salih Orovcanec, Nikola Dimovska-Jordanova, Vesna |
author_sort | Ivanovska Adjievska, Biljana |
collection | PubMed |
description | AIM: We aimed to evaluate the 1-year efficacy and safety of low-frequency intravitreal bevacizumab in the treatment of macular edema due to retinal vein occlusions (RVOs). METHODS: The study comprised an interventional prospective study of patients with macular edema due to central retinal vein occlusion (CRVO) or branch retinal vein occlusion, followed for 12 months. Treatment-naïve patients with reduced best-corrected visual acuity (BCVA) and central macular thickness (CMT) of at least 250 μm received intravitreal injection of bevacizumab. After 1 month, BCVA and optical coherence tomography (OCT) images of the macula were recorded. In patients with <30% improvement in BCVA and CMT, two more injections were applied at 1.5-month intervals. In all other patients, further injections were applied as needed. In cases with ischemic areas of retina, laser photocoagulation of the retina was performed. RESULTS: In total, 33 patients with CRVO and 55 with BRVO were treated. After 1 year, 65 eyes (73.86%) had clinically significant improvement of BCVA (>0.3 log of the minimum angle of resolution [logMAR] units) with average number of injections of 1.98. Improvement of mean BCVA in CRVO was significant (P=0.001) from baseline (1.2±0.95 logMAR units) to 1 year (0.75±0.6 logMAR units). Significant improvement of mean BCVA (P<0.001) was also found in BRVO, from 0.71±0.75 logMAR units at baseline to 0.28±0.5 logMAR units at 1 year. Baseline CMT was 852.21±298.20 μm for CRVO and 597.95±185.63 μm for BRVO. In both groups, there was significant decrease (P<0.001) in CMT after 1 year of treatment. Panretinal laser photocoagulation was done in 75.8% of all eyes with CRVO and sectoral photocoagulation in 49.1% of eyes with BRVO. CONCLUSION: In macular edema due to RVO, intravitreal bevacizumab provides improvement in visual acuity and reduction of macular edema in a high percentage of treated eyes after 1 year, even with low number of injections. |
format | Online Article Text |
id | pubmed-5488787 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-54887872017-08-08 The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions Ivanovska Adjievska, Biljana Boskurt, Salih Orovcanec, Nikola Dimovska-Jordanova, Vesna Clin Ophthalmol Original Research AIM: We aimed to evaluate the 1-year efficacy and safety of low-frequency intravitreal bevacizumab in the treatment of macular edema due to retinal vein occlusions (RVOs). METHODS: The study comprised an interventional prospective study of patients with macular edema due to central retinal vein occlusion (CRVO) or branch retinal vein occlusion, followed for 12 months. Treatment-naïve patients with reduced best-corrected visual acuity (BCVA) and central macular thickness (CMT) of at least 250 μm received intravitreal injection of bevacizumab. After 1 month, BCVA and optical coherence tomography (OCT) images of the macula were recorded. In patients with <30% improvement in BCVA and CMT, two more injections were applied at 1.5-month intervals. In all other patients, further injections were applied as needed. In cases with ischemic areas of retina, laser photocoagulation of the retina was performed. RESULTS: In total, 33 patients with CRVO and 55 with BRVO were treated. After 1 year, 65 eyes (73.86%) had clinically significant improvement of BCVA (>0.3 log of the minimum angle of resolution [logMAR] units) with average number of injections of 1.98. Improvement of mean BCVA in CRVO was significant (P=0.001) from baseline (1.2±0.95 logMAR units) to 1 year (0.75±0.6 logMAR units). Significant improvement of mean BCVA (P<0.001) was also found in BRVO, from 0.71±0.75 logMAR units at baseline to 0.28±0.5 logMAR units at 1 year. Baseline CMT was 852.21±298.20 μm for CRVO and 597.95±185.63 μm for BRVO. In both groups, there was significant decrease (P<0.001) in CMT after 1 year of treatment. Panretinal laser photocoagulation was done in 75.8% of all eyes with CRVO and sectoral photocoagulation in 49.1% of eyes with BRVO. CONCLUSION: In macular edema due to RVO, intravitreal bevacizumab provides improvement in visual acuity and reduction of macular edema in a high percentage of treated eyes after 1 year, even with low number of injections. Dove Medical Press 2017-06-21 /pmc/articles/PMC5488787/ /pubmed/28790803 http://dx.doi.org/10.2147/OPTH.S137380 Text en © 2017 Ivanovska Adjievska et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Ivanovska Adjievska, Biljana Boskurt, Salih Orovcanec, Nikola Dimovska-Jordanova, Vesna The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions |
title | The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions |
title_full | The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions |
title_fullStr | The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions |
title_full_unstemmed | The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions |
title_short | The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions |
title_sort | outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488787/ https://www.ncbi.nlm.nih.gov/pubmed/28790803 http://dx.doi.org/10.2147/OPTH.S137380 |
work_keys_str_mv | AT ivanovskaadjievskabiljana theoutcomeoflowfrequencyintravitrealbevacizumabtherapyformacularedemainretinalveinocclusions AT boskurtsalih theoutcomeoflowfrequencyintravitrealbevacizumabtherapyformacularedemainretinalveinocclusions AT orovcanecnikola theoutcomeoflowfrequencyintravitrealbevacizumabtherapyformacularedemainretinalveinocclusions AT dimovskajordanovavesna theoutcomeoflowfrequencyintravitrealbevacizumabtherapyformacularedemainretinalveinocclusions AT ivanovskaadjievskabiljana outcomeoflowfrequencyintravitrealbevacizumabtherapyformacularedemainretinalveinocclusions AT boskurtsalih outcomeoflowfrequencyintravitrealbevacizumabtherapyformacularedemainretinalveinocclusions AT orovcanecnikola outcomeoflowfrequencyintravitrealbevacizumabtherapyformacularedemainretinalveinocclusions AT dimovskajordanovavesna outcomeoflowfrequencyintravitrealbevacizumabtherapyformacularedemainretinalveinocclusions |